Quinuclidine Ester M3 Antagonists for Localized Lung Action
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current muscarinic M3 receptor antagonists used for treating respiratory diseases like asthma and COPD often have systemic side effects due to their absorption and lack localized action, with a desire for compounds that can be administered by inhalation and provide long-lasting bronchodilation without systemic toxicity.
Innovation Solution
Development of quinuclidine ester analogues of 1-azaheterocyclylacetic acid, which act as selective M3 receptor antagonists, designed to be rapidly metabolized into inactive forms after administration, allowing for localized action in the lungs while minimizing systemic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If quaternary ammonium salts are used as M3 receptor antagonists to achieve bronchodilation, then therapeutic effect is improved, but systemic side effects increase due to absorption and lack of localized action
Solution Approach 1:
The patent applies local quality by designing compounds with specific physicochemical properties (low solubility in water, high lipophilicity) that enable localized action in the lungs through inhalation administration. The compounds remain primarily at the site of administration (lungs) and are rapidly metabolized by pulmonary enzymes, creating a local therapeutic effect while minimizing systemic exposure and side effects.
Solution Approach 2:
The patent segments the drug's lifecycle into distinct phases: rapid pulmonary metabolism into inactive metabolites followed by excretion. This segmentation ensures that the active compound acts locally in the lungs and is quickly converted to inactive forms, preventing systemic circulation and reducing harmful systemic effects while maintaining therapeutic efficacy.
2Object-affected harmful factors
If compounds are designed for rapid metabolism into inactive forms to reduce systemic effects, then safety is improved, but duration of action may be reduced
Solution Approach 1:
The patent implements periodic action through repeated dosing regimens (e.g., twice daily or three times daily inhalation) of the active compound. Each dose provides a brief period of localized action followed by rapid metabolism, creating a cyclical pattern that maintains therapeutic effect in the lungs over extended periods without accumulating systemically, thus achieving both safety and sustained duration of action.
Data Source
AI summary
The invention relates to compounds of formula (I), wherein A, R1, R2, X, m and n are as defined in the specification, as selective M3 receptor antagonists, process for their preparation, composition comprising them and the therapeutic use thereof. Said compounds may be used in the treatment of, inter alia, a respiratory disease such as asthma and COPD.